Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients

NCT03084952 is registered in ClinicalTrials.gov with Infan Industria Quimica Farmaceutica Nacional as lead sponsor.

NCT NCT03084952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03084952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Unicentric Clinical Trial With Dose Scaling for Safety, Tolerability and Efficacy Assessment of 18-Methoxycoronaridine Administered to Cutaneous Leishmaniasis Patients
Lead sponsor
Infan Industria Quimica Farmaceutica Nacional
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2021
Completion date
July 31, 2024
Enrollment
52 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

drug side effect, leishmaniasis; american, cutaneous